Edition:
India

Ovid Therapeutics Inc (OVID.OQ)

OVID.OQ on NASDAQ Stock Exchange Global Select Market

8.90USD
18 Jan 2018
Change (% chg)

-- (--)
Prev Close
$8.90
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
17,614
52-wk High
$15.70
52-wk Low
$5.28

Chart for

About

Ovid Therapeutics Inc. (Ovid) is a biopharmaceutical company. The Company is engaged in developing medicines for patients and families living with rare neurological disorders. Its lead drug candidate is OV101. The Company’s second lead drug candidate is OV935. OV101 (gaboxadol) is a delta-selective GABAA receptor agonist. Ovid... (more)

Overall

Beta: --
Market Cap(Mil.): $206.16
Shares Outstanding(Mil.): 24.60
Dividend: --
Yield (%): --

Financials

BRIEF-Ovid Therapeutics Announces TAK-935/OV935 Granted Orphan Drug Designation By U.S. FDA For Treatment Of Lennox-Gastaut Syndrome

* OVID THERAPEUTICS ANNOUNCES TAK-935/OV935 GRANTED ORPHAN DRUG DESIGNATION BY U.S. FDA FOR TREATMENT OF LENNOX-GASTAUT SYNDROME

20 Dec 2017

BRIEF-Ovid Therapeutics Announces OV101 Granted Fast Track Designation By U.S. FDA For Treatment Of Angelman Syndrome

* OVID THERAPEUTICS ANNOUNCES OV101 GRANTED FAST TRACK DESIGNATION BY U.S. FDA FOR TREATMENT OF ANGELMAN SYNDROME

19 Dec 2017

BRIEF-Ovid Therapeutics Announces TAK-935/Ov935 Has Received Orphan Drug Designation From U.S. FDA For Treatment Of Dravet Syndrome

* OVID THERAPEUTICS ANNOUNCES TAK-935/OV935 HAS RECEIVED ORPHAN DRUG DESIGNATION FROM U.S. FDA FOR TREATMENT OF DRAVET SYNDROME

05 Dec 2017

BRIEF-Ovid Therapeutics Announces OV101 Shows Comparable Pk Profile In Phase 1 Study Of Adolescent Patients

* OVID THERAPEUTICS ANNOUNCES OV101 SHOWS COMPARABLE PK PROFILE IN PHASE 1 STUDY OF ADOLESCENT PATIENTS AND AMENDS PHASE 2 STARS CLINICAL TRIAL PROTOCOL TO INCLUDE ADOLESCENTS

29 Nov 2017

BRIEF-Ovid Therapeutics Q3 loss per share $0.38

* Ovid Therapeutics reports third quarter 2017 financial results and corporate progress

10 Nov 2017

BRIEF-Ovid Therapeutics announces first patient randomized in phase 1b/2a clinical trial of TAK-935

* Ovid Therapeutics announces first patient randomized in phase 1b/2a clinical trial of TAK-935/OV935 in adults with rare epilepsies Source text for Eikon: Further company coverage:

21 Aug 2017

BRIEF-Ovid Therapeutics Q2 loss per share $0.57

* Ovid Therapeutics reports second quarter 2017 financial results and corporate progress

11 Aug 2017

Earnings vs. Estimates